Agenus: HC Wainwright Raises PT to $23, Reiterates Buy Rating

Agenus: HC Wainwright Raises PT to $23, Reiterates Buy Rating

In a recent update, Agenus Inc. (Nasdaq: AGEN) announced a virtual Stakeholder Briefing on August 27, 2025, at 4:00 p.m. ET. The event will provide a strategic and financial overview, update on the Zydus partnership, and discuss the company's pipeline of immuno-oncology treatments, including Botensilimab (BOT) and Balstilimab (BAL) [1].

HC Wainwright & Co. Inc. has raised its price target for Agenus Inc. to $23, reiterating its Buy rating. The firm's analysts highlighted the company's robust pipeline and the potential of its combination therapy of Botensilimab and Balstilimab. The analysts believe that the company's focus on colorectal cancer (CRC) studies and its Phase 3 BATTMAN study in metastatic CRC positions Agenus well for future growth [2].

Agenus is a leading immuno-oncology company with a comprehensive pipeline of immunological agents, including Botensilimab and Balstilimab. Botensilimab is a multifunctional, human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Balstilimab is a novel, fully human monoclonal IgG4 designed to block PD-1 from interacting with its ligands PD-L1 and PD-L2. Both agents have shown clinical responses across various tumor types [1].

The upcoming Stakeholder Briefing will feature presentations from key executives and experts, including Garo H. Armen, PhD, Founder, Chairman, and CEO of Agenus; Richard M. Goldberg, MD, Chief Development Officer; and Nicholas C. DeVito, MD, Assistant Professor of Medical Oncology at Duke University. The session will also include a spotlight on MiNK Therapeutics, a significant stakeholder of Agenus [1].

The analysts at HC Wainwright & Co. Inc. expect that Agenus' pipeline and strategic partnerships, such as the one with Zydus, will drive the company's growth and success in the immuno-oncology space. The firm's positive outlook is reflected in its price target increase and Buy rating for Agenus Inc. [2].

References:
[1] https://www.marketscreener.com/news/agenus-aug-27-stakeholder-webcasta-transformative-io-updates-bot-bal-data-battman-preview-zydus-ce7c50d9da8bf12d
[2] https://www.hcwainwright.com/